Evidence map›Paper›PMID 39353949›Full record

ArticleNature communications2024

A plasmonic biosensor pre-diagnostic tool for Familial Mediterranean Fever.

Idil Karaca Acari, Fatma Kurul, Meryem Beyza Avci, S Deniz Yasar, Seda Nur Topkaya, Ceyhun Açarı, Erbil Ünsal, Balahan Makay, Süleyman Köytepe, Burhan Ateş and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Idil Karaca Acari *Department of Engineering Basic Sciences, Faculty of Engineering and Natural Sciences, Malatya Turgut Ozal University, Yesilyurt, Malatya, Turkey.ORCID 0000-0001-6783-7030
Fatma Kurul *Izmir Biomedicine and Genome Center, Balcova, Izmir, Turkey.
Meryem Beyza AvciIzmir Biomedicine and Genome Center, Balcova, Izmir, Turkey.
S Deniz YasarIzmir Biomedicine and Genome Center, Balcova, Izmir, Turkey.
Seda Nur TopkayaDepartment of Analytical Chemistry, Faculty of Pharmacy, Izmir Katip Celebi University, Cigli, Izmir, Turkey.
Ceyhun AçarıDepartment of Pediatrics, Faculty of Medicine, Inonu University, Battalgazi, Malatya, Turkey.ORCID 0000-0002-7175-0015
Erbil ÜnsalDivision of Pediatric Rheumatology, Faculty of Medicine, Dokuz Eylul University, Balcova, Izmir, Turkey.
Balahan MakayDivision of Pediatric Rheumatology, Faculty of Medicine, Dokuz Eylul University, Balcova, Izmir, Turkey.
Süleyman KöytepeDepartment of Chemistry, Faculty of Arts and Science, Inonu University, Battalgazi, Malatya, Turkey.
Burhan AteşDepartment of Chemistry, Faculty of Arts and Science, Inonu University, Battalgazi, Malatya, Turkey.
İsmet YilmazDepartment of Chemistry, Faculty of Arts and Science, Inonu University, Battalgazi, Malatya, Turkey.ORCID 0000-0002-7204-1050
Turgay SeçkinDepartment of Chemistry, Faculty of Arts and Science, Inonu University, Battalgazi, Malatya, Turkey.
Arif E CetinIzmir Biomedicine and Genome Center, Balcova, Izmir, Turkey. arifengin.cetin@ibg.edu.tr.ORCID 0000-0002-0788-8108

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 952346Türkiye Bilimsel ve Teknolojik Araştirma Kurumu (Scientific and Technological Research Council of Turkey) 119E649
6 · The paper itself

Abstract

Familial Mediterranean Fever (FMF) is an autosomal recessive genetic disorder, primarily observed in populations around the Mediterranean Sea, linked to MEFV gene mutations. These mutations disrupt inflammatory responses, increasing pyrin-protein production. Traditional diagnosis relies on clinical symptoms, family history, acute phase reactants, and excluding similar syndromes with MEFV testing, which is expensive and often inconclusive due to heterozygous mutations. Here, we present a biosensor platform that detects differences in pyrin-protein levels between healthy and affected individuals, offering a cost-effective alternative to genetic testing. Our platform uses gold nanoparticle-based plasmonic chips enhanced with anti-pyrin antibodies, achieving a detection limit of 0.24 ng/mL with high specificity. The system integrates an optofluidic system and visible light spectroscopy for real-time analysis, with signal stability maintained for up to six months. Our technology will enhance FMF diagnosis accuracy, enabling early treatment initiation and providing a cost-effective alternative to genetic testing, thus improving patient care.

Indexed as

Biosensing TechniquesFamilial Mediterranean FeverGoldMetal NanoparticlesPyrinGenetic TestingHumansLimit of DetectionMutationGoldMEFV protein, humanPyrin

Identifiers

PMID39353949
PMCPMC11445562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.